Dicyclomine (Dicycloverine) is a potent and orally active antagonist of muscarinic cholinergic receptors. Dicyclomine is an antispasmodic agent which relieves smooth muscle spasm of the gastrointestinal tract in vivo. Dicyclomine has high affinity for muscarinic M1 receptor subtype and M2 receptor subtype with Ki values of 5.1 nM and 54.6 nM in brush-border membrane and basal plasma membranes, respectively [1] [2].

Dicyclomine (Dicycloverine) (intraperitoneal injection; 8 mg/kg; daily) exacerbates the cognitive impairments in all the measurements. In addition, the memory impairments are worse in dicyclomine-treated 3xTg-AD mice compared to dicyclomine-treated NonTg mice [2].Dicyclomine (Dicycloverine) (intraperitoneal injection; 2.0, 4.0, and 8.0 mg/kg; 7 days) produces a highly significant effect on performance in the paired-associates learning (PAL) task in mice.And systemic treatment at lower doses show behavioral impairments in mice in spatial tasks [3]. Animal Model: C57Bl/6 mice [1] Dosage: 2.0, 4.0, and 8.0 mg/kg Administration: Intraperitoneal injection; daily; 7 days Result: Produced impairments due to actions of the agent outside of the hippocampus.